Effect of Antacids (Mg-Al-based) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257)

Trial Profile

Effect of Antacids (Mg-Al-based) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257)

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Imatinib (Primary) ; Aluminium hydroxide/magnesium hydroxide
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Eosinophilia; Fibroma; Gastrointestinal stromal tumours; Malignant melanoma; Myelodysplastic syndromes; Polycythaemia vera; Prostate cancer; Sarcoma; Scleroderma; Systemic mastocytosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 08 Apr 2009 Actual end date changed from Dec 2007 to Oct 2008 as reported by ClinicalTrials.gov.
    • 20 Dec 2007 Status changed from recruiting to completed.
    • 03 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top